HCPCS Level II drug code
J0713 — Injection, ceftazidime, per 500 mg
In short
J0713 is the HCPCS Level II code for injection, ceftazidime, per 500 mg. CMS assigns NDCs for Ceftazidime and Tazicef to it. One billing unit is 500 mg. The Medicare Part B payment limit is $1.549 per unit (October 1, 2026 through December 31, 2026).
Code
CMS HCPCS file- Descriptor
- Injection, ceftazidime, per 500 mg
- Short descriptor
- Inj ceftazidime per 500 mg
- Code set
- HCPCS Level II, maintained by CMS
- Effective
- Jan 1, 1997
The billing unit is read from the descriptor. Confirm it against the CMS file before billing.
Medicare Part B payment limit
CMS ASP fileEffective October 1, 2026 through December 31, 2026. Payment allowance limits subject to the ASP methodology are based on 2Q26 ASP data. A payment limit is not a coverage decision; the Medicare contractor decides coverage. CMS ASP pricing files
Units and claim line
Units = dose given ÷ 500 mg. For example, 50000 mg is 100 units. Enter the dose to get the units and the NDC line for the CMS-1500 and the 837P.
Enter the dose given to build the claim line.
NDCs billed under J0713
CMS’s ASP NDC–HCPCS crosswalk (effective October 1, 2026 through December 31, 2026) assigns 15 NDCs to J0713 for Ceftazidime and Tazicef. Billing units per package are CMS’s figures for this code’s unit.
| Drug | NDC (11-digit) | Labeler | Package | Billing units per package |
|---|---|---|---|---|
| Ceftazidime | 25021-0127-20 | Sagent Pharmaceuticals | 25 × 1 | 50 |
| Ceftazidime | 25021-0127-66 | Sagent Pharmaceuticals | 25 × 1 | 50 |
| Ceftazidime | 25021-0128-50 | Sagent Pharmaceuticals | 10 × 1 | 40 |
| Ceftazidime | 25021-0128-67 | Sagent Pharmaceuticals | 10 × 1 | 40 |
| Ceftazidime | 25021-0129-69 | Sagent Pharmaceuticals | 6 × 1 | 72 |
| Ceftazidime | 25021-0129-99 | Sagent Pharmaceuticals | 6 × 1 | 72 |
| Ceftazidime | 44567-0235-25 | WG Critical Care, LLC | 25 × 1 | 50 |
| Ceftazidime | 44567-0236-10 | WG Critical Care, LLC | 10 × 1 | 40 |
| Ceftazidime | 44567-0237-06 | WG Critical Care, LLC | 6 × 1 | 72 |
| Tazicef | 00409-5082-10 | Pfizer Inc | 10 × 1 | 20 |
| Tazicef | 00409-5082-16 | Pfizer Inc | 25 × 1 | 50 |
| Tazicef | 00409-5084-11 | Pfizer Inc | 10 × 1 | 40 |
| Tazicef | 00409-5086-11 | Pfizer Inc | 10 × 1 | 120 |
| Tazicef | 00409-5092-16 | Pfizer Inc | 25 × 1 | 50 |
| Tazicef | 00409-5093-11 | Pfizer Inc | 10 × 1 | 40 |
J0713: common questions
- Is J0713 a CPT code?
- No. J0713 is a HCPCS Level II code, maintained by CMS, that identifies the drug supplied. CPT codes are five-digit numbers from the AMA that describe services. Giving the drug, for example an injection or infusion, is usually reported with a separate CPT administration code. CPT codes for drug administration.
- What NDCs are billed under J0713?
- CMS's ASP crosswalk for October 1, 2026 through December 31, 2026 lists 15 NDCs under J0713, for Ceftazidime and Tazicef. The table on this page shows each one with its billing units per package.
- What is the Medicare payment limit for J0713?
- $1.549 per 500 mg, effective October 1, 2026 through December 31, 2026, from CMS's Part B drug payment limit file. Multiply by the units billed for the allowed amount before deductible and coinsurance. It is not a coverage decision.
- What is one billing unit of J0713?
- One unit of J0713 is 500 mg, as stated in the code's descriptor. Units to report = dose given ÷ 500 mg. J-code billing units.